Q2 2017 Earnings Estimate for Alnylam Pharmaceuticals, Inc. (ALNY) Issued By Leerink Swann
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Investment analysts at Leerink Swann lifted their Q2 2017 earnings estimates for Alnylam Pharmaceuticals in a report released on Thursday. Leerink Swann analyst P. Matteis now expects that the biopharmaceutical company will post earnings per share of ($1.15) for the quarter, up from their previous forecast of ($1.22). Leerink Swann currently has a “Market Perform” rating and a $67.00 price objective on the stock. Leerink Swann also issued estimates for Alnylam Pharmaceuticals’ Q3 2017 earnings at ($1.11) EPS, Q4 2017 earnings at ($1.02) EPS, FY2017 earnings at ($4.53) EPS and FY2018 earnings at ($4.96) EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Friday, May 5th. The biopharmaceutical company reported ($1.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.22) by $0.03. The business had revenue of $19 million during the quarter, compared to the consensus estimate of $22.91 million. Alnylam Pharmaceuticals had a negative return on equity of 42.90% and a negative net margin of 705.11%. Alnylam Pharmaceuticals’s revenue was up 160.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.21) earnings per share. ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.dailypolitical.com/2017/08/08/q2-2017-earnings-estimate-for-alnylam-pharmaceuticals-inc-alny-issued-by-leerink-swann.html.
Other equities analysts also recently issued reports about the company. Morgan Stanley restated an “equal weight” rating on shares of Alnylam Pharmaceuticals in a research report on Monday, July 10th. Chardan Capital set a $95.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, May 5th. BMO Capital Markets began coverage on Alnylam Pharmaceuticals in a research report on Monday, April 17th. They issued an “outperform” rating and a $73.00 price objective on the stock. Ladenburg Thalmann Financial Services set a $80.00 price objective on Alnylam Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, May 17th. Finally, Vetr downgraded Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $71.50 price objective on the stock. in a research report on Monday, May 15th. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Alnylam Pharmaceuticals has a consensus rating of “Buy” and an average price target of $79.79.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 82.93 on Monday. The company’s market capitalization is $7.15 billion. The firm has a 50-day moving average price of $80.45 and a 200-day moving average price of $59.96. Alnylam Pharmaceuticals has a 52 week low of $31.38 and a 52 week high of $86.92.
In other Alnylam Pharmaceuticals news, SVP Laurie Keating bought 11,500 shares of the company’s stock in a transaction on Tuesday, May 30th. The stock was acquired at an average price of $65.35 per share, for a total transaction of $751,525.00. Following the completion of the transaction, the senior vice president now directly owns 11,500 shares of the company’s stock, valued at $751,525. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Akshay Vaishnaw sold 43,750 shares of the business’s stock in a transaction that occurred on Monday, May 15th. The shares were sold at an average price of $65.00, for a total value of $2,843,750.00. Following the transaction, the senior vice president now owns 43,047 shares of the company’s stock, valued at approximately $2,798,055. The disclosure for this sale can be found here. Insiders have sold 64,125 shares of company stock valued at $4,325,000 in the last 90 days. Company insiders own 4.30% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. First Manhattan Co. acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $135,000. CIBC Asset Management Inc acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $221,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Alnylam Pharmaceuticals during the first quarter valued at about $148,000. Capstone Asset Management Co. acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $232,000. Finally, Hemenway Trust Co LLC acquired a new position in shares of Alnylam Pharmaceuticals during the second quarter valued at about $235,000. Institutional investors and hedge funds own 88.96% of the company’s stock.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.